- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Interventions
- Cemiplimab, Standard of care
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 832
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, TNBC - Triple-Negative Breast Cancer
- Interventions
- RTX-224
- Drug
- Lead sponsor
- Rubius Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 2 more
- Conditions
- Locally Advanced Unresectable Uveal Melanoma
- Interventions
- Tebentafusp-Tebn
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
- Interventions
- GoC intervention
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Interventions
- AU-007, Aldesleukin, Avelumab, Nivolumab
- Drug
- Lead sponsor
- Aulos Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Interventions
- Naltrexone
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
- Interventions
- AMXT1501, DFMO
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
- Conditions
- Melanoma
- Interventions
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Biological · Device
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Ipilimumab, Sargramostim
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 257
- States / cities
- Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
- Interventions
- CTX-8371
- Drug
- Lead sponsor
- Compass Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Margate, Florida • Orlando, Florida • Sarasota, Florida + 6 more
- Conditions
- Advanced Melanoma
- Interventions
- Nivolumab + Relatlimab, Nivolumab + Ipilimumab, Immunotherapy monotherapy, BRAF/MEK inhibitors
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Melanoma
- Interventions
- fianlimab, cemiplimab, relatlimab+nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 106
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
- Interventions
- IDOV-Immune (oncolytic vaccinia virus)
- Biological
- Lead sponsor
- ViroMissile, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • San Antonio, Texas
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- CB-839, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
- Conditions
- Solid Tumours, Melanoma
- Interventions
- BI 3810944
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Interventions
- NN3201
- Drug
- Lead sponsor
- Novelty Nobility, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
- Conditions
- Melanoma, Skin Cancer
- Interventions
- talabostat (PT-100) tablets, cisplatin
- Drug
- Lead sponsor
- Point Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Santa Monica, California • Aurora, Colorado + 9 more
- Conditions
- Refractory Cutaneous Melanoma
- Interventions
- Ipilimumab, Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Unresectable Stage III or Stage IV Melanoma
- Interventions
- CR011-vcMMAE
- Drug
- Lead sponsor
- CuraGen Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- Santa Monica, California • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Melanoma, Advanced Melanoma
- Interventions
- Gleevec, Temodar
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Melanoma
- Interventions
- bortezomib, sorafenib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Vemurafenib
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 8 more
- Conditions
- Melanoma
- Interventions
- ATN-224, Temozolomide
- Drug
- Lead sponsor
- Attenuon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Encinitas, California • Orange, California + 13 more
- Conditions
- Solid Tumor, Adult, Solid Tumor Cancer
- Interventions
- DF6215, pembrolizumab, KEYTRUDA®
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 5 more